Директен банков превод Western Union, Moneygram
Pomalong 4mg is an antineoplastic drug, which is used by the patients who are having a valid prescription and under the supervision of medical oncologist.
Pomalong 4mg affects the immune system. It encourages immune responses to help reduce tumor growth.
The primary indication of Pomalong 4mg is used in the treatment of Multiple Myeloma condition.
In this condition, Pomalong 4mg is used by interaction with dexamethasone.
Pomalong 4mg capsules are indicated in Patients already got therapy with two medications such as proteasome inhibitor & Lenalidomide. followed within 60 days in patients who are concluded the last treatment.
Pomalong tablets are available in the strength of 1mg, 2mg and 4mg
Pomalidomide is a thalidomide analogue; it is used in combination with dexamethasone
The recommended dose of Pomalong tablets in multiple myeloma condition, 4mg should be taken orally as a single dose on days 1-21 of repeated 28 days cycles until disease advancement
Pomalong given in combination with low dose of dexamethasone
Dexamethasone should be given orally only in days of 1, 8, 15 and 22 of each 28 days
>75 years: 20mg/day
≤75 years: 40mg/day
Pomalidomide therapy should be discontinue, if toxicities occur after dose reduction to 1mg (in case of neutropenia and thrombocytopenia)
<18 years: the safety and efficacy of the Pomalong tablets has been established
Pomalong tablets should be taken with water; it should not chew, break or open
Pomalong should be taken with or without food
Pomalong combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide.
No specific antidote is used for over dosage of Pomalidomide. Patient should be provided with general supportive measures. Monitor the signs & symptoms
Pomalong 4mg combination with CYP1A2 drugs causes increased concentration of Pomalidomide.
Overcome this problem by decreasing the dose of Pomalong 4mg during this combination therapy.
Thalidomide associate which evoke immunomodulatory and antineoplastic activity; it prohibits replication and induced apoptosis of hematopoietic tumor cells
Additionally, it increases T-cell and natural killer cell-mediated immunity and restrain production of TNF-alpha and interleukin-6; down-modulates cell surface adhesion molecules contain in leukocyte migration.
Anticancer activity may be due to inhibition of angiogenesis
Absorption: The peak plasma concentration time of Pomalidomide is arrives between 2 to 3 hours.
Distribution: Pomalidomide is bounded to human plasma protein by range of 12% & 44%.
Metabolism: The metabolism of Pomalidomide is appears via hepatically mediated through CYP1A2, CYP3A4.
Elimination: The Pomalidomide clearance value is 7 to 10L/hr.
Doses are excreted via urine 73% & feces 15% respectively.
The half-life period of Pomalidomide is 9.5 hours
Pomalong 4mg is contraindicated to;
Hypersensitivity reactions produced due to patients are contraindicated to the component of Pomalong 4mg.
Pregnancy category of Pomalong 4mg is X. Pomalong 4mg usage during pregnancy period, leads to fetal harm and causes death.
Breast feeding should not be recommended.
The Pomalong 4mg capsules container should be stored at 20oC to 25oC
Protect the container from moisture, heat, & light.
If missed dose occurs, consult with physician & follow the regular dosing schedule. Or skip the missed dose and follow the routine timing. Otherwise Missed dose leads to over dosage condition.
Check out the stock offers. It's nice to save!Покажи всички